Drug intelligence / Profile preview

4P025

Development stage: Preclinical
Lead developer: Delta4
Modality: Small Molecules

Overview

4P025 is a chemical drug candidate in early-stage development for the treatment of primary sclerosing cholangitis and other liver diseases. The precise mechanism of action for 4P025 has not been disclosed or remains unknown. The drug is being developed through a partnership between Delta 4, an AI technology company based in Vienna, Austria, and 4P-Pharma, a French biotechnology company. As of the latest updates, its highest development status is at the discovery stage with no clinical trial data or approvals reported[1][2][3][5].

Beyond the preview

Go deeper on 4P025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4P025.

Explore the full profile